Abstract:Embryonic stem cell pathways such as hedgehog and Wnt pathways are central to the tumorigenic properties of cancer stem cells (CSC). Since CSCs are characterized by their ability to self-renew, form differentiated progeny, and develop resistance to anticancer therapies, targeting the Wnt and hedgehog signaling pathways has been an important strategy for cancer treatment. Although molecules targeting either Wnt or hedgehog are common, to the best of our knowledge, those targeting both pathways have not been documented. Here we report a small molecule (compound 1) that inhibits both Wnt (IC50 = 0.5 nM) and hedgehog (IC50 = 71 nM) pathways based on reporter gene assays. We further identified that the molecular target of 1 for Wnt pathway inhibition was porcupine (a member of the membrane-bound O-acyltransferase family of proteins), a post-translational modification node in Wnt signaling; while the target of 1 mitigating hedgehog pathway was Smoothened, a key G protein coupled receptor (GPCR) mediating hedgehog signal transduction. Preliminary analysis of structure-activity-relationship identified key functional elements for hedgehog/Wnt inhibition. In in vivo studies, compound 1 demonstrated good oral exposure and bioavailability while eliciting no overt toxicity in mice. An important consideration in cancer treatment is the potential therapeutic escape through compensatory activation of an interconnected pathway when only one signaling pathway is inhibited. Toward this end, compound 1 may not only lead to the development of new therapeutics for Wnt and hedgehog related cancers, but may also help to develop potential cancer treatment which needs to target Wnt and hedgehog signaling simultaneously.

Design, Synthesis, and Evaluation of Potent Wnt Signaling Inhibitors Featuring a Fused 3-Ring System.

Design, Synthesis, and Evaluation of Novel Porcupine Inhibitors Featuring a Fused 3-Ring System Based on the 'reversed' Amide Scaffold.

Exploration of the Linkage Elements of Porcupine Antagonists Led to Potent Wnt Signaling Pathway Inhibitors.

The Development of Highly Potent Inhibitors for Porcupine.

Discovery and Characterization of a Potent Wnt and Hedgehog Signaling Pathways Dual Inhibitor.

Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974

Design, synthesis, and evaluation of pyrrolo[2,1-f][1,2,4]triazine derivatives as novel hedgehog signaling pathway inhibitors.

Inhibiting The Wnt Signaling Pathway With Small Molecules

Novel PORCN inhibitor WHN-88 targets Wnt/β-catenin pathway and prevents the growth of Wnt-driven cancers

Design, Synthesis, and Biological Study of 6,7-Dihydro-5 H -Pyrano[2,3-d]pyrimidine Derivatives As Novel Hedgehog Signaling Pathway Inhibitors

Identification and biological evaluation of fused tetrahydroisoquinoline derivatives as Wnt/β-catenin signaling inhibitors to suppress colorectal cancer

Small-Molecule Inhibitors Targeting the Canonical WNT Signaling Pathway for the Treatment of Cancer

Design, Synthesis, and Biological Evaluation of Novel Phenol Ether Derivatives As Non-Covalent Proteasome Inhibitors.

Discovery of Novel 4-(2-pyrimidinylamino)benzamide Derivatives As Highly Potent and Orally Available Hedgehog Signaling Pathway Inhibitors

Synthesis and Pharmacological Evaluation of Trifluoromethyl Containing 4-(2-pyrimidinylamino)benzamides As Hedgehog Signaling Pathway Inhibitors

Five-membered Heteroaromatic Ring Fused-Pyrimidine Derivatives: Design, Synthesis, and Hedgehog Signaling Pathway Inhibition Study.

Synthesis of Potent Dishevelled PDZ Domain Inhibitors Guided by Virtual Screening and NMR Studies

Synthesis and Biological Evaluation of Novel Benzamide Derivatives As Potent Smoothened Antagonists.

Discovery and Characterization of a Small Molecule Inhibitor of the PDZ Domain of Dishevelled

Discovery of potent, orally bioavailable, small-molecule inhibitors of WNT signaling from a cell-based pathway screen

Novel 4-(2-pyrimidinylamino)benzamide derivatives as potent hedgehog signaling pathway inhibitors.